Frank V. Fossella, MD
Dr. Frank V. Fossella is a thoracic medical oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. He has been providing expert patient care to patients diagnosed with malignant mesothelioma and lung cancer for almost 50 years and has distinguished himself through research seeking treatment options that deliver improved patient outcomes.[1]
Education and Career
Dr. Fossella attended Cornell University in Ithaca, New York for his undergraduate degree, graduating with a Bachelor of Arts degree in Biology. He earned his medical degree at Baylor College of Medicine in Houston, Texas, and remained at Baylor to complete an internship and residency in Internal Medicine and a fellowship in Medical Oncology.[1]
Research
Dr. Fossella has served as the principal investigator for lung cancer clinical trials, conducting and reporting on studies ranging from phase I to phase III. He developed and participated in over 50 clinical studies and has reported on them as author and co-author in a wide range of highly respected peer-reviewed publications.
Recent clinical trials include:[2]
- Enrollment Status: Terminated
- Publish Date: July 15, 2022
- Intervention Type: Drug, Biological
- Study Drugs: IL-2, Fludarabine, Cyclophosphamide
- Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
- Enrollment Status: Completed
- Publish Date: April 19, 2022
- Intervention Type: Drug, Biological
- Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
- Study Phase: Phase 1/Phase 2
Recent publications include:[2]
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Journal: Lancet (London, England). Published: June 20, 2023
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. Journal: Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Published: May 17, 2023
Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. Journal: JCO oncology practice. Published: February 23, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. Journal: JTO clinical and research reports. Published: January 26, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Journal: Cancer. Published: September 30, 2022
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Journal: Lung cancer (Amsterdam, Netherlands). Published: August 22, 2022
